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Small intestine allotransplantation in humans is not 
yet feasible due to the failure of the current methods of 
immunosuppression. FK-506, a powerful new immuno-
suppressive agent that is synergistic with cyc1osporine, 
allows long-term survival of recipients of cardiac, renal, 
and hepatic allografts. This study compares the effects 
of FK-506 and cyclosporine on host survival, graft re-
jection, and graft-versus-host-disease in a rat small in-
testine transplantation model. Transplants between 
strongly histoincompatible ACI and Lewis (LEW) strain 
rats, and their F) progeny are performed so that graft 
rejection alone is genetically permitted (FI-+LEW) or 
GVHD alone permitted (LEW-+F 1) or that both immu-
nologic processes are allowed to occur simultaneously 
(ACI-+LEW). Specific doses of FK-506 result in pro-
longed graft and host survival in all genetic combina-
tions tested. Furthermore, graft rejection is prevented 
(ACI-+LEW model) or inhibited (rejection only model) 
and lethal acute GVHD is eliminated. Even at very high 
doses, cyc1osporine did not prevent graft rejection or 
lethal GVHD, nor did it allow long-term survival of the 
intestinal graft or the host. Animals receiving low doses 
of cyc1osporine have outcomes similar to the untreated 
control groups. No toxicity specific to FK-506 is noted, 
but earlier studies by other investigators suggest oth-
erwise. 
Small intestine allotransplantation (SIA)* that results in the 
establishment of grafts capable of absorbing nutrients and 
supporting human life has not yet been achieved, despite the 
demonstration of its technical feasibility 30 years ago (1). The 
limiting obstacle in all SIA models examined to date remains 
the failure of traditional methods of immunosuppression, in-
cluding cyclosporine, to prevent rejection. Since the introduc-
1 This work was supported by Research Grants from the Veterans 
Administration and Project Grant No. DK-29961 from the National 
Institutes of Health, Bethesda, MD. 
2 Reprint requests should be sent to: A. L. Hoffman, M.D., Depart-
ment of Surgery, 5 Center Falk Clinic, 3601 Fifth Avenue, Pittsburgh, 
PA 15213. 
* Abbreviations: ALG, antirat lymphocyte globulin; SIA, small in-
testine allotransplantation. 
tion of CsA, some progress in long-term survival following SIA 
in rats and larger animals has been reported (2-6). Recently, 
6-month survival has been achieved following human small 
intestine allotransplantation (7) as well as multivisceral organ 
transplantation, which included the entire small intestine and 
most of the colon (8). However, failures are more common than 
temporary successes. This is particularly distressing in light of 
the fact that the number of patients who would potentially 
benefit from SIA and who have been otherwise relegated to 
total parenteral nutrition or worse is significant (9). 
It is clear that future improvements of SIA will depend upon 
the development of more-specific and less-toxic forms of im-
munosuppression. FK -506 is a powerful new immunosuppres-
sant that has recently been demonstrated to successfully inhibit 
hepatic (10), renal (11), and cardiac (12) rejection in animal 
models. 
The purpose of the present study was to compare the effects 
of FK-506 and CsA on host survival, graft rejection, and graft-
versus-host disease in a rat small intestine transplantation 
model. 
MATERIALS AND METHODS 
Animals. Male Lewis (LEW) (RTl'), ACI (RT1") strains, and 
(ACIxLEWlF, hybrid rats weighing 200-300 g were purchased from 
Harlan Sprague Dawley (Indianapolis, IN). The rats were housed in a 
conventional animal facility, fed rat chow (Wayne Lab Blox F -6, 
Chicago, ILl and tap water ad libitum. Rats are allowed to acclimatize 
for at least 1 week prior to investigation. Using the two parental strains 
and their F 1 progeny, fully or semiallogeneic graft transfers were 
examined. These donor/recipient combinations made it possible to 
independently study graft rejection EcF"-~ibtF or donor-mediated 
GVHD (LEW ..... F) or their simultaneous occurrence in combination 
(ACI ...... LEW) (13). 
Immunosuppressive Agents 
FK -506: FK -506 was supplied in powder form by the Fujisawa 
Pharmaceutical Company, Ltd., Osaka, Japan. The properties 
and immunosuppressive activity of this drug have been recently 
described (10-12). All concentrations of drug were made up in 
sterile normal saline and administered to experimental animals 
using deep intramuscular hind-limb injections. Dosages are 
listed in Table 1. 
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II 
Group 
A 
B 
C 
A 
B 
C 
III 
IV 
V 
VI 
VII 
VIII 
TABLE l. 
n 
11 
8 
14 
10 
10 
8 
8 
9 
11 
7 
9 
6 
Group classification and treatment regimens 
Donor Recipient Treatment (days)a 
--------
ACI L 
F, L 
L F, 
ACI L FK 2 mg/kg/qd (0-6); 1 
mg/kg/qod (8-30) 
F, L FK 2 mg/kg/qd (0-6); 1 
mg/kg/qod (8-30) 
L F, FK 2 mg/kg/qd (0-6); 1 
mg/kg/qod (8-30) 
ACI L FK 2 mg/kg/qd (3-6) 
ACI L ALG (donor) 100 mg/ 
kg/qd (-2, -1); FK 2 
mg/kg/qd (3-6) 
ACI L CsA 15 mg/kg/qd, 0-6/ 
qod (8-30) 
ACI L CsA 20 mg/kg/qd, 0-6/ 
qod (8-30) 
ACI L CsA 40 mg/kg/qd (-2-
7) 
L F, CsA 20 mg/kg/qd (-2-
14) 
a Qd, treatment once daily; and qod, treatment every other day. 
CsA: CsA was supplied in powder form by Sandoz Pharma-
ceutical Corporation (East Hanover, NJ). The drug was dis-
solved in Mygliol (Dynamit Nobel, Witten/Ruhr, West Ger-
many), an oil-based carrier, and administered as described for 
FK -506. Dosages are listed in Table 1. 
ALG: Goat antirat lymphocyte globulin (ALG) was a gift 
from Dr. Richard Condie (University of Minnesota Hospitals, 
Minneapolis, MN). The final protein concentration was 42.7 
mg/ml. A dose of 100 mg/kg/day was injected i.p. on days -2 
and -1 to group IV donors. 
Operative techniques. No preoperative manipulation of food 
and water was necessary. Donor anesthesia was induced with 
3.6% chloral hydrate by intraperitoneal injection at 1 ml/lOO g 
of body weight. Heterotopic jejunoileal allotransplantation was 
performed as described previously.3 Briefly, the intestinal seg-
ment was removed from the donor based upon a pedicle of the 
superior mesenteric artery and vein. The vascular and alimen-
tary lumina were flushed with 3 ml of lactated Ringer's solution 
containing 150 U of porcine heparin and 30 ml of 1 % neomycin 
solution, respectively. All solutions were maintained at 4°C. 
The recipients were anesthetized as described for the donors, 
and 20 mg/kg of Cefoxitin (Merck, Sharp and Dohme, West 
Point, P A) was injected intraperitoneally to inhibit enteric 
bacterial contamination. Donor superior mesenteric artery to 
host aorta and donor superior mesenteric vein to host infrarenal 
vena caval anastomoses were performed with continuous 9-0 
Novafil. A Thiry-Vella loop was fashioned with the oral seg-
ment emanating from the right lower abdominal quadrant and 
the aboral segment projecting from the right upper abdominal 
quadrant. Animals surviving less than 5 days were considered 
technical failures and were excluded from the data analysis. 
The technical success rate was approximately 80%. 
Experimental groups. Eight groups were assessed for graft 
3 Hoffman AL, Makowka L, Cai X, et a1. Near-total heterotopic 
small intestine transplantation in the rat (submitted for publication). 
and host survival as well as clinical and histologic evidence of 
graft rejection and/or GVHD. The specifics of the treatment 
protocol are listed in Table 1. FK-506 was found in a screening 
study to be most effective at the doses used in group II. The 
dose and schedule used in group III were similar to that used 
to prevent graft rejection and to prolong host survival following 
cardiac allotransplantation in the rat (12). Treatment with 10 
ml/kg of rabbit antirat ALG (protein concentration unknown) 
for 2 days prior to transplantation has been previously dem-
onstrated to prevent GVHD in a semiallogeneic parent to F, 
rat small intestine transplantation model (14). CsA at 15 mg/ 
kg for days 0-6 and every other day for days 8-30 has been 
reported to prolong graft and host survival following Brown-
Norway (BN) ~ LEW small bowel transplants (4). Higher 
doses of CsA were used to increase the effectiveness of the 
immunosuppression in the ACf~ LEW model of small intes-
tine transplantation. 
Clinical monitoring. The recipients were evaluated daily for 
graft failure, and the rats were weighed every 2-3 days. The 
transplanted bowel was gently decompressed/daily, and acute 
rejection was manifested as progressive stomal ischemia and 
death of the animal once the initial 4-day period had elapsed. 
Chronic rejection was diagnosed as the onset of a right-sided, 
firm abdominal mass that occurred more than 30 days following 
transplantation. GVHD was established when 4 of the 6 clinical 
signs were present: diffuse erythema, hyperkeratosis ofthe foot 
pads, dermatitis, unkempt appearance, diarrhea, weight loss 
(15). 
Histologic monitoring. Ear and intestinal stoma biopsies were 
taken at random in a limited number of animals. All recipients 
were necropsied following euthanasia or at death. Ear, tongue, 
donor and recipient small intestine, liver, and pancreas were 
removed and processed routinely for light microscopy. All sec-
tions were reviewed by a surgeon (ALH) and pathologist (BB) 
blinded to the drug therapy. 
The following histologic features were assessed: mucosal 
integrity, villous architecture, and type and location of inflam-
matory cells. "Apoptosis" was defined as single-cell necrosis 
within the epithelium. "Cryptitis" was defined as single or 
multiple necrotic cells limited to the crypts. "Endothelialitis" 
was defined as lymphocyte adherence to endothelium that 
invariably showed evidence of injury. 
A diagnosis of acute rejection was made if there was multi-
focal cryptitis (>3 crypts involved per high-power field) with 
or without a mononuclear cell inflammatory infiltrate in the 
lamina propria, and/or endothelial or perivascular inflamma-
tion. Mucosal necrosis, ulceration, and sloughing were consid-
ered consistent with rejection and were diagnosed as such when 
the surrounding intact bowel displayed cryptitis or a mononu-
clear cell infiltrate. Chronic rejection was diagnosed when there 
was obliteration of the bowel architecture secondary to fibrosis 
without other lesions consistent with ischemia or infection. 
GVHD in the tongue, ear, and liver was recognized as mul-
tifocal apoptosis with lymphocyte infiltration. In host intestine, 
a diagnosis of GVHD was made if multi focal cryptitis was 
present with or without inflammation in lamina propria. 
The histologic similarity of rejection and GVHD, in some 
cases, made it necessary to know the origin of the small intes-
tine prior to establishing a definitive diagnosis. 
Statistical analysis_ Host survival data were evaluated using 
Kaplan-Meier survival plots. Generalized savage (Mantel-Cox) 
statistical analysis of the plots were performed. Statistical 
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comparisons of acute or chronic rejection or GVHD between 
groups was performed using Chi-square analysis with Yates 
correction. A value of P<0.05 was considered to be statistically 
significant. 
effects specific to FK-506 or CsA were demonstrated in this 
experimental protocol. 
Bidirectional, fully allogeneic model (groups lA, IIA, IIl-VII). 
RESULTS 
General. The results of our experiments clearly demonstrate 
that FK-506 is more effective than CsA in preventing acute 
rejection and lethal GVHD in this model of SIA in the rat. The 
survival of all groups studied are listed in Tables 2-4. No toxic 
Control animals (group IA) died from acute rejection at 7.3± 
1.0 days. All the other groups in these experiments, except 
those animals receiving low-dose CsA (group V), had statisti-
cally significant prolongation of host survival (Table 2). The 
longest mean survival and most effective inhibition of acute 
rejection, both clinically and histologically, occurred with FK-
506 (group HA). Even very high doses of CsA (group VII) were 
TABLE 2. Host survival, clinical rejection, and GVHD in a bidirectional fully allogeneic model EACf~ibtF of small intestine transplantation 
in the rat 
-----
-----
Group Treatment" Survival times (days) Mean survival P value' Acute Chronic GVHD n ±SD (days) rejection rejection 
---------
IA 11 9,9,8,7,7,7,7,7, 7.3±1.0 11/11 0/11 0/11 
7,6,6 
IIA 10 FK long 131, 118, 96, 38, 36, 50.6±46.5 0.0001 0/10' 5/10' 0/10 
course 33,25,13,9,7 
III 8 FK short 76,73,63,31, 11, 34.9±30.8 0.0008 3/8 3/8 0/8 
course 10,8,7 
IV 9 ALG (do- 79,40,25,21,11,8, 22.3±24.2 0.0324 5/9 2/9 0/9 
nor), FK 7,5,5 
short 
course 
V 11 CsA 15 long 24,9,9,8,8,7, 7,6, 8.5±5.3 0.7441 9/11 0/11 0/11 
course 6,5,5 
VI 7 esA 20 long 23, 13, 11, 10, 9, 7, 5 11.1±5.8 0.0150 7/7 0/7 0/7 
course 
VII 9 CsA 40 short >114,69,28,27,26, 34.3±35.2 0.0007 4/9 1/9 0/9 
course 16,15,8,6 
a Refer to Table 1. 
, Generalized savage (Mantel-Cox) value comparing survival times to that of untreated controls. 
, Chi-square, P value <0.05. 
TABLE 3. Host survival and clinical rejection in a unidirectional, semiallogeneic model ([AClxLEWj F1->LEW) of small intestine 
transplantation in the rata 
Group 
IB 
lIB 
n 
8 
10 
Treatment Survival times (days) 
12,11,10,9,9,8,7,6 
FK long course >206, >205, >139,117, 
32, 23, 12, 12, 8, 8 
a Genetically restricted to graft rejection; GVHD is not possible in this model. 
Mean survival 
±SD (days) 
9.0±2.0 
83.0±82.6 
b Generalized savage (Mantel-Cox) value comparing survival times to that of untreated controls. 
"Chi-square, P value <0.05. 
-------
P value' Acute Chronic 
rejection rejection 
8/8 0/8 
0.0022 3/10' 1/10 
TABLE 4. Host survival and clinical GVHD in a unidirectional, semiallogeneic model Eibt~[AClxibtl F 1) of small intestine 
transplantation in the rata 
Group n 
Ie 14 
lIC 8 
VIII 6 
Treatment' 
FK long course 
esA 20 inter-
mediate 
course 
Survival times (days) 
25, 24, 21, 17, 17, 16, 12, 
11,11,10,9,8,7,7 
>214, >214, >213, >213, 
>212, >206, >202, 7 
>104,53,50,8,7,7 
Mean survival 
+SD (days) 
13.9±6.1 
188.0±72.1 
38.3±38.6 
P value" GVHD 
6/14 d 
0.0002 1/8e•1 
0.1035 2/6 
,------------------------------
a Genetically restricted to GVHD; graft rejection is not possible in this model. 
b Refer to Table 1. 
'Generalized savage (Mantel-Cox) value comparing survival times to that of untreated controls. 
d Four other animals demonstrated findings suggestive of GVHD. 
e Chi-square, P value <0.05. 
1 Lone animal that developed GVHD is alive with resolution of the disease. 
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not as effective as FK-506 in prolonging survival or inhibiting 
acute rejection. 
Although acute rejection was prevented in the ACf~ibt 
model by FK-506 (group IIA), chronic rejection occurred in 
50% of the rats in this group. FK-506 used in low doses (data 
not shown), short schedules (group Ill), or combined with ALG 
donor pretreatment (group IV) was not successful in preventing 
acute or chronic rejection. Grait and host survival was signifi-
cantly less in these groups than in group IIA. The use of 
A 
equivalent doses of ALG alone did not confer prolongation of 
host survival relative to the untreated controls. 
Severe acute rejection was seen in histologic sections of the 
donor intestine from the control and CsA-treated groups but 
not in the FK-506-treated rats (group HA) (Fig. 1). In the CsA 
treated group (group VII), multifocal cryptitis, lamina propria 
inflammation, and endothelialitis were prominent and progres-
sive. Chronic rejection was detected histologically, but not 
clinically, in a single animal from the CsA group. Acute rejec-
B 
c 
FIGuRE L Donor small intestine, fully allogeneic bidirectional model: A. control animal (group IA) at 8 days showing cryptitis and 
inflammation of the lamina propria (H&E; x lOO); B. FK -50G--treated animal (group IIA) at 22 days showing normal villi and crypts (H&E; x63); 
and C. CsA-treatecl animals (group VII) at 26 (hy" d,'monstrating severe cryptitis and inflammation in the lamina propria (H&E; XlOO). 
,-----,.,-,-----
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tion was not present in the animals treated with FK-506 (group 
IIA), but histologic evidence of chronic rejection correlated 
with the clinical findings of an indurated intestinal graft with 
luminal obliteration and abscess formation resulting in death 
of the host within 30 days of onset of the lesion. 
G VHD was not demonstrated clinically in the bidirectional 
model, although the histopathologic lesions associated with this 
syndrome were present in the control and all treatment groups. 
The host intestine, ear, tongue, and liver were affected to 
variable degrees (Fig. 2). 
Weight gain was observed in the posttransplantation period 
for both FK-506 and CsA. Late weight loss correlated with the 
onset of chronic rejection in the FK-506 treatment group (IlA) 
(Fig. 3A). 
Unidirectional, semiallogeneic model of graft rejection (groups 
IB, JIB). Control animals (group IE) died of acute graft rejec-
tion 9.0±2.0 days posttransplantation. FK -506-treated rats 
(group IIB) had a mean survival of 83 days (Table 3). In this 
model FK-506 inhibited, but did not prevent, acute rejection 
(group lIB). Three of 10 rats died of acute rejection while 
receiving FK-506 (group IIB). The histopathologic lesions in 
this group were much less severe when compared to the control 
group (Fig. 4). The FK -506-treated animals had cryptitis alone, 
while the control group had cryptitis with lamina propria 
inflammation and, commonly, mucosal necrosis. Progressive 
weight gain was present in the FK-506 group (group lIB) but 
not in the control group (Fig. 3B). 
Unidirectional, semiallogeneic model of GVHD (groups IC, 
JIC, VIII). Control animals that received donor small bowel 
transplants in a combination that allowed for the development 
of GVHD without graft rejection died in 13.9±6.1 days. Six 
died with clinical manifestations of GVHD, and four others 
died with 3/6 clinical signs of GVHD. FK-506 (group lIe) 
prevented fatal GVHD and prolonged mean survival to 188.0± 
FIGURE 2. Host small intestine, control animal (group lA, fully 
allogeneic model) at 8 days with GVHD that is characterized by 
cryptitis and lamina propria inflammation (H&E; XIOO). 
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FIGURE 3. Postoperative weight change following small intestine 
transplantation in the rat. A. Fully allogeneic model-progressive 
weight gain is noted in the FK-506-treated rats (group HAJ. Following 
a several-month period of well-being, chronic rejection resulted in 
weight loss and death of the animals. Only high doses of CsA (group 
VII) resulted in weight gain in the recipients. The remaining survivor 
is alive and thriving at >3 months posttransplantation. B. Semiallo-
geneic model of rejection after an initial period of slight loss, the 
surviving FK-506-treated animals gained weight. Control animals lost 
weight and died in a short period of time. C. Semi allogeneic model of 
GVHD-the FK-506-treated animals show progressive weight gain. 
The CsA-treated group gained weight until the late onset of lethal 
GVHD resulted in weight loss and death. 
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FIGURE 4. Donor small intestine, semiallogeneic rejection model: A. 
control animal (group IB) at 8 days showing severe rejection with 
villous blunting, cryptitis, and inflammation (H&E; XlOO); and B. FK-
506-treated animal (group lIB) at 12 days demonstrating rare single-
cell necrosis (arrow) and minimal inflammation (H&E; X125). . 
72.1 days (Table 4). Seven of eight remain alive and well, 
including a single rat that developed clinical GVHD at 53 days 
posttransplant that then resolved in 2 weeks. CsA treatment 
(group VIII) delayed, but did not prevent GVHD, and two 
animals died with the syndrome at 50 and 53 days. Three 
animals died of unknown causes, perhaps secondary to a sub-
clinical form of GVHD. FK-506 treatment was effective enough 
to be associated with a progressive weight gain beginning 9 
days posttransplantation (Fig. 3C). 
In histologic sections, florid G VHD was present, as expected, 
in the control animals (group IC) (Fig. 5A). The lesions were 
more extensive than the bidirectional ACI ..... LEW controls with 
frequent single-cell necrosis, cryptitis, and moderate to severe 
lamina propria inflammation. The FK-506-treated rats in this 
donor/recipient combination (group IIC) were not sacrificed, 
and no histopathologic comparisons could be made with the 
control group. However, 2 ear biopsies from group IIC animals 
did not display any evidence of GVHD (Fig. 5B). As expected, 
there was no clinical nor histologic evidence of rejection of the 
donor intestine in the LEW ..... F, model at any time. 
DISCUSSION 
Small intestine allotransplantation has important potential 
for clinical application as an effective therapy modality for the 
many manifestations of short-bowel syndrome. The operation 
can be technically accomplished in a variety of species, includ-
FIGURE 5. Sections of ear, semiallogeneic GVHD model: A. control 
animal (group IC) at 25 days with apoptosis throughout the basal layer 
and lymphocytic infiltrate in the dermis; and B. FK-506-treated animal 
(group lIe) at 21 days with normal skin (H&E; x125). 
ing man, and progress has been made since the introduction of 
CsA (2-8, 16). However, the application of this procedure is 
restricted because of the failure of traditional methods of im-
munosuppression, including CsA, to prevent graft rejection. 
Multiple investigators have recently demonstrated that the use 
of the new immunosuppressive agent, FK-506, is an effective 
means of preventing the rejection of cardiac, renal, and hepatic 
allografts (10-12). In these studies, we have examined the 
effectiveness of FK-506, as compared to CsA, as an immuno-
suppressive agent in a rat small intestine allotransplantation 
model. These experiments were conducted in a highly histoin-
compatible ACI ..... LEW donor/recipient strain combination 
and one that allowed us to independently examine the effect of 
these agents on graft rejection and GVHD. 
The results of our experiments demonstrate that FK -506 is 
a more effective single agent than CsA in the prevention of 
acute rejection and lethal GVHD. In the fully allogeneic and 
semiallogeneic rejection models, FK -506 prolonged graft and 
host survival, allowed a higher yield of long-term survivors and 
significantly inhibited or prevented (bidirectional model only) 
clinical and histologic manifestations of acute rejection when 
compared to CsA-treated or control animals (Tables 2-3). In 
the semiallogeneic model in which only graft-versus-host dis-
ease is genetically possible, FK -506 preD~ented lethal acute 
GVHD, decreased the incidence of clinical GVHD, and was 
associated with long-term disease-free survival in 7/8 animals 
(Table 4). CsA was capable of ablating or at least inhibiting 
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GVHD during its administration, but a fatal syndrome ensued 
approximately 1 month following cessation of treatment. 
Though early studies by Tutschka et al. (I7) had been prom-
ising, many investigators have demonstrated that CsA is not 
completely effective in the prevention of GVHD following bone 
marrow (I 8, 19) or small bowel transplantation (20). The 
prevention of acute lethal GVHD by FK-506 represents a 
distinct therapeutic advantage for this agent. 
The results also demonstrated a dose effect for each of the 
immunosuppressive agents and the variable effectiveness of 
CsA when tested across different histoincompatibility barriers. 
The dose of FK-506 used in group II was very effective as 
outlined above. Reduction of the dose by 75% with the same 
schedule and route of administration (data not shown) resulted 
in acute rejection and the death of 4/5 animals in 8-17 days. 
In this ACI-+LEW model, higher doses of CsA were slightly 
more effective than lower doses of the drug in prolonging graft 
and host survival and in inhibiting acute rejection. However, 
in a BN -+ LEW SIA model (4), the regimen of CsA as used 
in group V was effective in securing high-yield, long-term host 
survival suggesting that it is easier to suppress rejection in this 
strain combination. Doses of CsA that were 25% larger or 
several times greater were unable to overcome the problem of 
graft rejection or allow prolonged graft or host survival in the 
ACI-+ LEW strain combination when compared to low doses 
of FK-506. Hatcher et al. (21) also had low-yield, long-term 
survival when using oral esA in an ACI-->LEW small intestine 
transplantation model. Erratic uptake of intramuscular CsA 
that is dissolved in the lipid soluble carrier, Mygliol, has been 
described (22) and is also a possible explanation for this phe-
nomenon. 
The immunosuppressive properties of FK-506 and GVHD 
(23, 24) are well documented. Based on the histologic findings, 
GVHD and FK-506 may be additive or synergistic in the 
suppression of acute graft rejection. In the fully allogeneic 
control animals, rejection predominates. When appropriate 
doses of FK-506 are administered, rejection is not present 
though histologic evidence of GVHD persists. At these same 
doses of FK-506, if GVHD is genetically restricted, as in the 
F,-->LEW model, rejection can be seen clinically and histolog-
ically. Furthermore, donor pretreatment with ALG, which pre-
vents GVHD induced by small intestine transplantation (14), 
when used in conjunction with low-dose FK-506 does not 
prevent rejection and is associated with short survival times. 
Using only low-dose FK-506 without ALG, survival times are 
prolonged. A balance between graft rejection and GVHD has 
been suggested previously (25, 26). The relative predominance 
of either of these immunologic reactions is related to the length 
of the intestinal graft (number of immunocompetent cells 
transplanted) (25), the effectiveness of the immunosuppression 
(26), and other less well-defined factors, which may include 
species variation and immune responsiveness. 
These experiments demonstrate that FK-506 is a better 
single agent than CsA for prolonging graft and host survival, 
preventing acute graft rejection, and ablating lethal GVHD 
following rat small intestine allotransplantation. FK-506 is not 
however a pharmacologic panacea for the prevention of allo-
graft rejection although it represents a powerful addition to the 
immunosuppressive armentarium. Chronic rejection occurred 
in 50% of the recipients in the clinically relevant bidirectional 
model following cessation of FK-506, but protracted treatment 
may have prevented this complication. Though concerns about 
deleterious toxic side effects (27-29) are primarily based on the 
early work with this powerful immunosuppressive agent, more 
extensive and controlled toxicity studies involving FK-506's 
effects on various organs and species are clearly indicated. The 
possibility that FK-506 and CsA may be synergistic in their 
actions as immunosuppressive agents could prove to be clini-
cally important since the complimentary therapeutic effects 
may avoid much of the toxicity associated with the use of each 
agent independently. 
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